Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
Rusfertide, the subject of a 2024 tie-up, scores in phase 3.
BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
One step forward, two steps back for biotech.
Another SERD catalyst and the son of Darzalex take centre stage.
